TY - BOOK AU - Reymond,Marc A. AU - Solass,Wiebke TI - PIPAC: Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure SN - 9783110366624 PY - 2014/// CY - Berlin/Boston PB - De Gruyter KW - Antineoplastic agents KW - Aerosol KW - Antineoplastic Combined Chemotherapy Protocols KW - Peritoneal Neoplasms KW - drug therapy KW - Aerosols KW - therapeutic use KW - Carcinoma N1 - Includes bibliographical references at the end of each chapters and index; Preface; Acknowledgments; 1 Introduction; 2 Peritoneal carcinomatosis: a neglected disease; 2.1 An unmet medical need; 2.2 Role of the physician in provision of care in advanced peritoneal cancer; 2.3 Palliative care in peritoneal carcinomatosis; 3 Normal and diseased peritoneum; 3.1 Ontology; 3.2 Anatomy; 3.2.1 Blood supply; 3.2.2 Lymphatics; 3.2.3 Lymphatic stomata; 3.2.4 Milky spots; 3.2.5 Greater omentum; 3.2.6 Peritoneal nerves; 3.3 Physiology of peritoneum; 3.3.1 Peritoneum-plasma barrier; 3.3.2 Intraperitoneal Hydrostatic Pressure; 3.4 Pathophysiology of peritoneal carcinomatosis; 3.4.1 Epithelial-mesenchymal transition3.4.2 Interstitial intratumoral fluid pressure; 3.4.3 Ascites; 3.4.4 Hormonal changes; 4 Diagnosis and staging of peritoneal carcinomatosis; 4.1 Diagnostic workup; 4.2 Imaging studies; 4.2.1 Computer tomography (CT scan); 4.2.2 Magnetic Resonance Imaging (MRI); 4.2.3 Ultrasound; 4.2.4 FDG-Positron emission tomography (PET); 4.3 Diagnostic laparoscopy; 4.3.1 Peritoneal Cancer Index; 4.4 Peritoneal or pleural cytology; 4.4.1 Gastric cancer; 4.4.2 Ovarian cancer; 4.4.3 Colorectal cancer; 5 Therapy of peritoneal carcinomatosis; 5.1 Systemic palliative chemotherapy5.2 Intraperitoneal chemotherapy; 5.3 Drug uptake into tumoral tissue; 5.3.1 Diffusion; 5.3.2 Convection; 5.4 Effect of peritonectomy on drug clearance; 5.5 Influence of intraperitoneal drug concentration; 5.6 Tissue penetration of various drugs; 5.6.1 Doxorubicin (see also page 199); 5.6.2 Cisplatinum (see also page 198); 5.6.3 Oxaliplatinum; 5.6.4 Taxanes (Paclitaxel, Docetaxel); 5.7 Perioperative intraperitoneal chemotherapy; 5.7.1 CHPP; 5.7.2 NIPS; 5.7.3 EIPL; 5.7.4 EPIC; 5.8 Intraperitoneal chemotherapy for ascites; 5.9 Limitations of intraperitoneal chemotherapy5.9.1 Poor drug penetration; 5.9.2 Poor surface exposition; 5.9.3 Local toxicity; 5.9.4 Peritoneal sclerosis; 5.10 Intraperitoneal immunotherapy; 5.10.1 Catumaxomab; 5.10.2 Bevacizumab; 5.10.3 Immunoradiotherapy; 5.11 Intraperitoneal cytolytic virotherapy; 5.12 Nanodrugs; 5.13 Combined CRS with HIPEC; 5.13.1 Cytoreductive surgery (CRS); 5.13.2 Hyperthermic IntraPEritoneal Chemotherapy (HIPEC); 5.13.3 Colorectal cancer; 5.13.4 Ovarian Cancer; 5.13.5 Gastric Cancer; 5.13.6 Learning curve and expertise; 5.13.7 Evidence of cost effectiveness; 5.13.8 Safety5.13.9 Indications for CRS and HIPEC; 6 Assessing tumor response in peritoneal carcinomatosis; 6.1 Natural history of peritoneal carcinomatosis; 6.2 RECIST criteria; 6.2.1 RECIST criteria in peritoneal carcinomatosis; 6.3 Laparoscopy in peritoneal carcinomatosis; 6.4 Histology for determining tumor response; 6.5 Tumor markers for determining tumor response; 6.5.1 Gastric cancer; 6.5.2 Ovarian cancer; 6.5.3 Colorectal cancer; 6.6 Determining clinical benefit rate in peritoneal carcinomatosis; 7 Principle of therapeutic capnoperitoneum; 7.1 Material and methods; 7.1.1 Design of the prototype N2 - Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel approach for treating peritoneal carcinomatosis. First encouraging results have been obtained in human patients. UR - https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=887007 ER -